Back to News
Market Impact: 0.25
Elevar Submits EMA Marketing Application For Lirafugratinib In Cholangiocarcinoma
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Elevar Therapeutics, majority-owned by HLB Co., submitted a Marketing Authorisation Application to the European Medicines Agency for lirafugratinib as a second-line treatment for patients with advanced or metastatic disease. The filing advances the drug toward potential European commercialization, though regulatory approval remains uncertain.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Congress passes sweeping US sanctions bill targeting Russia
- House Passes Bill Allowing Trump Tariffs on Russian Oil Buyers
- Fed Rate Hike Looms as Retail Sales Surge
- OpenAI discloses six more instances of ’concerning’ AI model behavior
- The Fed decision, Clarity Act fails in Senate, Ford's truck prices and more in Morning Squawk
- Snap tries to bring AR glasses to enterprise market, partnering with Nvidia, AWS and Salesforce
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Capital IQ Alternatives for Research and Deal Work
- Research Workflows, Report Format Selection, and Interactive Synthesis